Symptoms and treatment when death is expected in dementia patients in long-term care facilities by unknown
Klapwijk et al. BMC Geriatrics 2014, 14:99
http://www.biomedcentral.com/1471-2318/14/99RESEARCH ARTICLE Open AccessSymptoms and treatment when death is expected
in dementia patients in long-term care facilities
Maartje S Klapwijk1,2*, Monique AA Caljouw1, Mirjam C van Soest-Poortvliet3, Jenny T van der Steen3
and Wilco P Achterberg1Abstract
Background: Although dementia at the end of life is increasingly being studied, we lack prospective observational
data on dying patients. In this study symptoms were observed in patients with dementia in the last days of life.
Methods: When the elderly care physicians in two Dutch nursing homes expected death within one week,
symptoms of (dis)comfort, pain and suffering were observed twice daily. For this the Pain Assessment in Advanced
Dementia (PAINAD; range 0–10), Discomfort Scale-Dementia of Alzheimer Type (DS-DAT; range 0–27), End-Of-Life in
Dementia-Comfort Assessment in Dying (EOLD-CAD; range 14–42) and an adapted version of the Mini-Suffering
State Examination (MSSE; range 0–9), were used. Information on care, medical treatment and treatment decisions
were also collected.
Results: Twenty-four participants (median age 91 years; 23 females), were observed several times (mean of 4.3
observations (SD 2.6)), until they died. Most participants (n = 15) died from dehydration/cachexia and passed away
quietly (n = 22). The mean PAINAD score was 1.0 (SD 1.7), DS-DAT 7.0 (SD 2.1), EOLD-CAD 35.1 (SD 1.7), and MSSE
2.0 (SD 1.7). All participants received morphine, six received antibiotics, and rehydration was prescribed once.
Conclusion: In these patients with dementia and expected death, a low symptom burden was observed with
validated instruments, also in dehydrated patients without aggressive treatment. A good death is possible, but
might be enhanced if the symptom burden is regularly assessed with validated instruments. The use of observation
tools may have influenced the physicians to make treatment decisions.
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It is estimated that, worldwide, about 35 million people
have dementia. Currently, 5% of people aged > 65 years
are diagnosed with dementia, increasing to more than
50% in the group aged 90 years and over [1-3]. In the first
stages of dementia people tend to live at home; however,
when the disease becomes more progressive, many people
with dementia are admitted to a long-term care facility
(LTCF) [4]. In the Netherlands, and also in other parts of
the world [5], LTCFs have specialized dementia care units.
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unless otherwise stated.specialized in care for vulnerable older people and the
chronically ill living in a LTCF [4,6-8].
The period between ascertainment of the diagnosis de-
mentia and death can take several years, with phases of
slight to moderate decline or fast decline in cognition
and functioning, depending on the type of dementia [9].
Internationally, many people with dementia die in
LTCFs; e.g. in the USA 67% and in the Netherlands up to
92% [10]. The 6-month mortality rate in LTCF residents
with advanced dementia is reported to be 18-37% [11,12].
The cause of death while dying with dementia has
been studied in the USA and the Netherlands [13,14].
The most frequently mentioned cause of death is cachexia
with dehydration (35%) [15]. Pneumonia and complica-
tions of cardiovascular disease were the second and third
mentioned cause of death, respectively, both around
20% [15].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dyspnea, agitation, anxiety, fear, crying, moaning, choking,
gurgling or difficult swallowing. During this period, mouth
care and the prevention of pressure ulcers, constipation
and urinary retention are also important [16-18]. People
with dementia are often incapable of expressing them-
selves verbally when they are uncomfortable or when they
suffer from symptoms. Therefore, observational or proxy-
rate instruments have been developed for people with ser-
ious cognitive impairment to measure the quality of dying;
some of these instruments have good psychometric prop-
erties [19].
Differences in treatment during the final phase of pa-
tients with dementia have been acknowledged. In many
countries (including the USA and some European coun-
tries) patients in the terminal phase too often receive
aggressive treatments that may be of limited clinical
benefit [14,20-24]. Especially the belief among many rela-
tives and health-care workers about an unpleasant death
when dehydrated, or the imagined effects of rehydra-
tion, may hamper a dignified and evidence-based pallia-
tive care [25,26].
Many studies have retrospectively described the symp-
toms in patients dying with dementia [14,18,20,27,28]. In
these studies, data were collected retrospectively before
and after death, to describe the experienced symptoms
in the period before death. However, prospective observa-
tional studies that systematically observe dying patients
with validated instruments are still lacking. Therefore, this
prospective observational follow-up study was performed
to describe the incidence and course of observed symp-
toms and treatment in people with dementia in the last
days before their expected death.
Methods
Setting and study population
This prospective observational follow-up study was part of
a study to validate methods of measurement of quality of
care and quality of dying with dementia in long-term care
facilities (LTCFs) in the Netherlands [19,29]. From January
2008 to February 2009 two elderly care physicians in two
LTCFs included patients if they met the following inclusion
criteria: residing in a LTCF for ≥ 30 days, a physician’s diag-
nosis of dementia and expected to die within the next
7 days. The expectancy of a patient to die within 7 days is
based on an estimation made by the treating physician and
the nurses caring for the patient, and is often related to the
fact that a patient has stopped eating and drinking [30].
The Medical Ethics review Committee of VU University
Medical Center Amsterdam approved the study. Families
were asked for permission for study participation by the
coordinating physician who also observed the patients.
Neither of the observing elderly care physicians were part
of the research group.Data collection
Two elderly care physicians collected data by filling out
observation instruments, i.e. the Pain Assessment In
Advanced Dementia (PAINAD), Discomfort Scale-Dementia
Alzheimer type (DS-DAT), End-of-Life in Dementia scales-
Comfort Assessment in Dying (EOLD-CAD), and the
Mini Suffering State Examination (MSSE).
Prior to the start of this study, these two physicians were
trained with an instructional video on the use of the DS-
DAT and the PAINAD. The observations of the patients
expected to die within 7 days were scheduled twice a day.
During the observation periods, the patients were in rest.
In the morning the PAINAD, the DS-DAT and the EOLD-
CAD were scored. The physician in charge of the medical
care observed the patient while sitting next to the patient
for 10 minutes per observation.
The second observation was in the afternoon. Again,
the physician observed the patient for 10 minutes and
then filled out the PAINAD, DS-DAT and the MSSE,
and additional questions regarding the course of the day.
Therefore, the DS-DAT and PAINAD were scored twice
a day (if possible), and the MSSE and EOLD-CAD once
a day.
The PAINAD is an instrument that is validated to ob-
serve pain in non-communicative patients with advanced
dementia [31]. The PAINAD contains 5 items which can
generate a score from 0–2. The total score ranges from
0–10, with 10 indicating severe pain. A score of 2 or higher
is used to give an indication of pain [32-34].
The DS-DAT measures discomfort in advanced de-
mentia patients. It consists of 9 items with four response
options ranging from 0–3. The total score ranges from
0–27, with 0 indicating ‘no discomfort’ and 27 indicating
‘the highest level of discomfort’ [35-37].
A tool to measure comfort at the end of life is the
EOLD-CAD. This observation scale scores symptoms
while dying with dementia and contains 14 items that
can be scored with a 1, 2 or 3 score. The symptoms in
the EOLD-CAD are the symptoms actually noticed at
the time of the observation. The total score ranges from
14–42, with a higher score indicating a higher level of
comfort for the patient [38,39].
Suffering was measured with the MSSE. The MSSE
measures symptoms in end-stage dementia patients and
gives an indication of suffering over the course of the
whole day [40,41]. The MSSE has 10 items. One item is
the family’s judgment regarding the suffering of the
patient. Because data regarding suffering as seen by
family members were retrospectively collected, these
question in the MSSE was not used to calculate the total
score; therefore, only the first 9 items were used for the
present study. The total score ranges from 0 (indicating
a low level of suffering) to 9 (indicating the highest level
of suffering).
Table 1 Baseline characteristics of the study population
(N = 24) and course of mortality
Socio-demographic factors
Female, n (%) 23 (95.8)
Dutch, n (%) 23 (95.8)
Widowed, n (%) 16 (66.7)
Mean age in years (SD) 90 (6.9)
Mean length of stay in months (SD) 32 (27.8)
Medical information
Dementia mean duration in months (SD) 49 (41.7)
Cognition
CPS
Level 0 Intact, n (%) 0 (0)
Level 1 Borderline intact, n (%) 1 (4.2)
Level 2 Mild impairment, n (%) 0 (0)
Level 3 Moderate impairment, n (%) 1 (4.2)
Level 4 Moderate severe impairment, n (%) 0 (0)
Level 5 Severe impairment, n (%) 9 (37.5)
Level 6 Very severe impairment, n (%) 13 (54.2)
BANS-S mean score (SD) 19 (5.4)
SD = Standard deviation.
CPS = Cognitive Performance Scale.
BANS-S = Bedford Alzheimer Nursing Severity-Scale.
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Within two weeks after death, the physician collected in-
formation about the participants’ gender, age, marital
status, length of stay at the LTCF, and duration of demen-
tia. Information on care, medical treatment (including
pain, and antipsychotic and anti-depressive medication),
and treatment decisions in the last 7 days before death
were also collected.
Cognition
In addition, the 7 category Minimum Data Set Cognitive
Performance Scale (CPS) was used to determine the cog-
nitive performance status. The CPS was scored within
2 weeks after death and concerned the last month of life.
The CPS is a valid measuring scale for cognitive per-
formance. This scale can range from intact (level 0), bor-
derline intact, mild, moderate, moderately severe and
severe impairment to very severe impairment (level 6) [42].
Also, the 7-item Bedford Alzheimer Nursing Severity-Scale
(BANS-S) was used to measure the severity of dementia in
the last month before death. Scores on the BANS-S range
from 7–28; a score of 17 and higher is regarded as severe
dementia [43,44].
Statistical analysis
Descriptive statistics were used to describe the study
population and observed symptoms; results are reported
as mean and standard deviation (SD) for normally dis-
tributed data, and median and interquartile range (IQR)
for non-normally distributed data. The t-test was used
to compare age, duration of stay at the LTCF and years
of dementia between the observed and non-observed
patients.
To dichotomize the presence of symptoms in the
EOLD-CAD the scores 1 = ‘a lot’ and 2 = ‘somewhat’ are
combined.
Descriptive statistics reported the mean and SD of the
observational instruments at each observation point be-
fore death.
All analyses were performed with SPSS statistical soft-
ware, version 20 (SPSS Inc., IBM, USA).
Results
Study population
During the study period from February 2008 to February
2009 in two Dutch LTCFs, a total of 36 patients died on
the wards in which the physicians were working. Of
these, 12 patients could not be included in the present
study because of sudden death (n = 5) or because the
physician did not have the opportunity to perform the
observations (n = 7), resulting in 24 participants available
for this study. Of these participants, 11 were observed
only one time and 13 were observed more frequently;
the mean number of observations was 4.3 (SD 2.6). Intotal, 80 observations were conducted by the two physi-
cians. All 24 participants died within 5 days; 12 of them
died within the first 2 days.
Of the 24 observed participants (23 females) the mean
age was 90 (SD 6.9) years. Mean length of stay in the
LTCF was 32 (SD 27.8) months. The mean duration of
dementia was 49 (SD 41.7) months. No difference in age
and length of stay was found between the 24 participants
and the 12 non-participants.
Cognition and severity of dementia before dying
About half of the participants (52.4%) had very severe
cognitive impairment. The mean BANS-S score was 19
(SD 5.4) (Table 1).
Symptoms of dying
The PAINAD was completed 61 times (missing 19 times);
for 39 of these ratings (63.9%) no indication of pain was
observed. There were 69 DS-DAT ratings (11 missing), 31
MSSE ratings (9 missing) and 40 EOLD-CAD ratings.
The mean PAINAD score was 1.0 (SD 1.7), the mean
DS-DAT score was 7.0 (SD 2.1), the mean EOLD-CAD
score was 35.1 (SD 1.7), and the mean MSSE score was
2.0 (SD 1.7). Figure 1 shows the course of the total scale
scores until death, which overall implies a low preva-
lence of symptoms.
The scores of the PAINAD for each participant resulted
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Figure 1 Mean score of observational instruments (with standard deviation) in last days to death.
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more points on the DS-DAT. Two participants (10%)
scored no symptoms of suffering on the MSSE.
Table 2 shows the symptoms of dying scored with the
MSSE and EOLD-CAD in the 7 days before death. The
MSSE was conducted 31 times, 7 of these ratings (22.6%)
had a score of 0, and 24 ratings (77.4%) had a score of
1–9, indicating some symptoms of suffering. In multiple
observations, symptoms such as pain were present 11
times (35.5%), malnutrition was present 13 times (41.9%),
eating disorders 12 times (38.7%) and suffering according
to medical opinion 10 times (32.3%).
For example, the observational instrument EOLD-CAD
scored discomfort among participants 15 times (37.5%),
shortness of breath 12 times (30%), serenity 34 times (85%),
peace 36 times (90%), and calmness 35 times (87.5%).
Treatment and medication
In the last days before death, 12 of the participants lost
consciousness. According to the physicians, 22 partici-
pants (91.7%) passed away quietly in the last 6 hours be-
fore death and 2 (8.3%) were aware of symptoms.
All 24 participants received morphine (one received a
dose that was higher than necessary for symptom con-
trol); for 19 participants (79,1%) it was not necessary to
increase the dose of morphine in the course of theterminal phase. In 4 patients (16.7%) there was a gradual
increase in the dosage of morphine and, in one patient
(4.2%), there was a substantial increase in the dosage on
the last day. Two participants were pharmacologically kept
sedated, in order to relieve the symptom burden. The
exact dosages of paracetamol, NSAIDs, anti-depressive
and antipsychotic medication, were not available for all
patients.
Six participants (25%) received antibiotics and one
(4.2%) received subcutaneous rehydration. The physicians
reported that they stopped antibiotics or oral medication
or rehydration in 13 (54.2%) of the participants, for one
participant (4.2%) they decided not to start antibiotics,
two participants were not sent to the hospital for surgery,
and for one participant no further diagnostic exploration
was started (Table 3).
The physicians also reported that no treatment was
stopped or withheld to induce death.
Five participants had an indwelling urinary catheter and
two received oxygen. All participants received mouth care,
and 19 treatments for the prevention of pressure ulcers
were conducted.
Cause of death
Fifteen participants (62.5%) died of cachexia/dehydration,
three of pneumonia (12.5%) and four (16.7%) due to a
Table 2 Symptoms present in multiple observations in ≤
7 days before death in all 24 patients
N %
MSSE 31 100
Restlessness/not calm 6 19.4
Screams 2 6.5
Pain 11 35.5
Decubitus ulcers 2 6.5
Malnutrition 13 41.9
Eating disorders 12 38.7
Invasive action 1 3.2
Unstable medical condition 4 12.9




Restlessness/not calm 7 17.5
Shortness of breath 12 30.0
Choking 4 10.0
Gurgling 2 5.0








MSSE =Mini-Suffering State Examination; missing n = 9.
EOLD-CAD = End-Of-Life in Dementia-Comfort Assessment in Dying.
Table 3 Medication/palliative care and cause of death ≤
7 days before death in the study population (N = 24)
N %
Medication/palliative care
Antibiotics, oral tablets 6 25.0
Morphine 24 100
Rehydration, hypodermoclyse 1 4.2
Stop antibiotics, oral medication or rehydration 13 54.2
Not starting treatment with antibiotics 1 4.2
Not starting treatment with surgical operation 2 8.3




Pneumonia (acute pulmonary disease) 3 12.5
Disease of the digestive system 4 16.7
Renal failure 1 4.2
Brain injury after a fall 1 4.2
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one died from brain injury after a fall (4.2%) (Table 3).
Discussion
This is one of the few studies that prospectively and
through direct physician observation explored the symp-
tomatology and treatment in the last days of life of pa-
tients with advanced dementia.
The low level of burdensome symptoms in the days be-
fore death, also in patients dying from dehydration/cachexia,
the low rate of aggressive curative treatment and the high
rate of palliative treatment with morphine are striking re-
sults. These data strengthen the recommendations for a
better tailored, less curative aggressive approach to pallia-
tive care in dementia [24,45].
A strength of this study is the prospective study design.
Retrospective designs in end of life care are particularly
sensitive for bias [46]. Particularly when people are easilyidentified to be at risk of dying (which was the case in this
study), this prospective approach is recommended [47].
Another strength is that this study used structured ob-
servations twice a day (with validated instruments) by
physicians specialised in the care for dementia patients
[19,48]. The results of the total scores of the observational
instruments showed no increase in symptom burden over
time, not even on the last days prior to death. This is a
remarkable contrast to the results seen in other retro-
spective studies, which showed an increase in burdensome
symptoms in the time prior to death [14,49].
This study also has some limitations. It was a relatively
small sample, there were missing observations, and the ob-
servations were performed by the elderly care physicians
who also were responsible for the treatment decisions.
Therefore, an important issue to consider is whether these
findings have been influenced by the study itself. Having a
physician who performs a structured observation of symp-
toms twice a day, might lead to an improved awareness
and assessment of symptomatology and, hence, to better
palliative treatment.
Studying symptoms of dying in patients with dementia is
challenging. Although differentiation between pain and, for
instance, anxiety or discomfort is difficult, in the present
study specific observational instruments were used. The
DS-DAT was specifically developed to measure discomfort
in advanced dementia, and the PAINAD was developed
and validated for the assessment of pain in people with de-
mentia [31-37]. The PAINAD has not been validated for
use in the last days of life. The item ‘breathing’ in the PAI-
NAD covers ‘noisy labored breathing’, ‘long periods of
hyperventilation’ or ‘Cheyne-Stokes respirations’. Cheyne-
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life and can be part of the normal physiological process
of dying. However, because we cannot differentiate be-
tween the three symptoms observed under ‘breathing’, we
cannot state exactly how many people exhibited Cheyne-
Stokes respirations.
The EOLD-CAD includes gurgling/death rattle but does
not include, for instance, nausea or vomiting, two symp-
toms that can also be unpleasant in the last days of life.
Also, the presence of a death rattle cannot differentiate be-
tween the underlying cause, for instance pneumonia or
the absence of coughing. The best treatment for death rat-
tle in dementia is morphine or an anticholinergic drug,
like scopolamine. However, more studies are needed to
determine the most effective treatment. It would be inter-
esting to repeat the present study and include independ-
ent, objective observers and also include observations
after a change in treatment. At the time of this study,
the validated instruments used were the best available.
These observational instruments help to structurally as-
sess symptoms in these patients, and can help to observe
symptoms and to assess the effect of the treatment re-
ceived for these symptoms.
All patients received morphine and, in 19 (79.1%) of
these patients, the dosage was not raised. We do not
want to imply that the use of morphine in the last days
of life with dementia is always necessary, but it is often
used to alleviate the burden of pain or dyspnea. In the
Netherlands, many patients receive the starting dose of
morphine (10–30 mg subcutaneously a day), for a con-
siderable period of time (days, weeks, sometimes even
months). Death is not considered to be a direct side-
effect of this medication in these dosages, and (as far as
we know) there is no evidence for any association be-
tween this treatment and death.
Elderly care physicians in the Netherlands are in
charge of the medical care of patients in the long-term
care facility [8]. They have received extensive training in
elderly care medicine, which includes palliative care. In
this study we decided to observe the patients when
death was expected within 7 days. The moment of death
can be more accurately predicted when the intake of fluid
or food has severely diminished; in the present study, the
result was that 50% of the patients died within 2 days
after the start of the observation. The cause of death was
assessed by the elderly care physicians who were fully
knowledgeable about the patient’s condition in the last
phase of life.
In the discussion about a good death, physician involve-
ment such as physician-assisted suicide, euthanasia, pallia-
tive sedation and withholding curative treatment are
heavily debated. In 2010, of all deaths in the Netherlands,
2.8% were the result of euthanasia, and 12.3% of the
deaths were the result of continuous deep sedation untildeath [50]. In a study covering the period 2007 to 2011 in
dementia patients, 21% received deep sedation [18]. How-
ever, euthanasia is very rare in patients with dementia (al-
though under Dutch law dementia is not an exclusion
criterion per se) and in the present study there were no
such cases. Also, for none of the patients in the present
study, was starting or withholding treatment performed
with the intention to induce death. This is in line with
the observation that, in the Netherlands, active phys-
ician involvement in inducing death in dementia patients
in long-term care is extremely rare [50]. Therefore, active
physician involvement in this setting seems to mainly con-
sist of pertinent palliative care principles.
Conclusion
In this study in patients with advanced dementia and ex-
pected death, a low symptom burden was observed with
validated instruments, also in dehydrated patients without
aggressive treatment. A good death is possible, but this
might be enhanced in a situation where symptom burden
is regularly assessed with validated instruments. Therefore,
we support others who recommend that proper symptom
assessment should be implemented in long-term care. The
use of observation tools may help physicians to take appro-
priate treatment decisions. All symptoms and preventive
measures should feed into a personalised tailored care plan
to help the patient and the (in)formal caregivers in the
process of dying with dementia.
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